Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Alternate-Day Buprenorphine Administration. Phase I - 3

This study has been completed.
University of Vermont
Information provided by:
National Institute on Drug Abuse (NIDA) Identifier:
First received: September 20, 1999
Last updated: June 23, 2005
Last verified: November 1993
The purpose of this study is to determine if two times a subject's daily maintenance dose will hold for 48 hours without changes in agonist and antagonist effects.

Condition Intervention Phase
Opioid-Related Disorders
Drug: Buprenorphine
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Alternate-Day Buprenorphine Administration. Phase I

Resource links provided by NLM:

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Drug use
  • Opioid withdrawal
  • Opioid agonist effects
  • Dose identification
  • Pupil diameter

Estimated Enrollment: 0
Study Start Date: April 1992

Ages Eligible for Study:   28 Years to 45 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Please contact site for information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000221

United States, Vermont
Treatment Research Center
Burlington, Vermont, United States, 05401
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
University of Vermont
Principal Investigator: Warren Bickel, Ph.D. University of Vermont
  More Information

Publications: Identifier: NCT00000221     History of Changes
Other Study ID Numbers: NIDA-06969-3  R01-06969-3 
Study First Received: September 20, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists processed this record on October 20, 2016